The China-based surgical robot manufacturer is gearing up for growth after receiving Europe’s CE mark last year for its single port endoscopic system.
Surgerii Robotics raises $100M to fund global expansion Read More »
The change runs counter to the company’s broader efforts to pare back red tape for physicians amid widespread discontent with health insurers.
UnitedHealthcare raises bar for doctors to get paid for radiology services Read More »
Johnson & Johnson’s filing comes a month after Medtronic gained U.S. clearance for its Hugo system as competition in the soft tissue robotic surgery market heats up.
J&J submits FDA de novo request for Ottava robot in general surgery Read More »
Piecemeal extensions of Medicare coverage for virtual services have impeded access to care, the American Medical Association argued. The policies could expire again on Jan. 30.
Provider, telehealth groups urge Congress to make telehealth flexibilities permanent Read More »
The company announced a $350 million public offering on Monday shortly after revealing positive Phase II results for its investigational congenital adrenal hyperplasia drug, with hopes to one day compete with Neurocrine’s Crenessity.
Crinetics Advances Potential Neurocrine Competitor With Fresh Data and Money Read More »
The cardiovascular biotech was also named as one of BioSpace’s top startups to watch on Wednesday.
Corsera Raises $80M as First Preventative Heart Disease Program Moves Into Clinic Read More »
Jazz’s Ziihera and BeOne’s Tevimbra plus chemotherapy led to what Truist Securities dubbed one of the strongest overall survival signals ever reported in a type of gastroesophageal cancer.
Jazz’s Ziihera Shows ‘Practice-Changing’ Efficacy in Stomach Cancer Read More »
Though specific data for bepirovirsen remain under wraps, GSK plans to file for approval in the first quarter of 2026.
GSK, Ionis Achieve Functional Cure in Hepatitis B Studies, Clearing Path for FDA Run Read More »
The acquisition is centered on Dark Blue Therapeutics’ small-molecule degrader of the MLLT1 and MLLT3 proteins, which is being tested for acute myeloid leukemia.
Amgen Makes Up To $840M Cancer Play With Dark Blue Takeover Read More »
Cartography will hunt for novel tumor antigens, which Pfizer can opt into and advance into clinical development.
Pfizer Searches for Novel Tumor-Selective Antigens With $865M+ Cartography Pact Read More »
